More News

Lotus Neuro launches to deliver therapies across blood-brain barrier

Jim Cornall -
Lotus Neuro, a clinical-stage biotechnology company pairing focused ultrasound with leading therapeutic modalities to treat focal neurologic disease, has...

Antibody targeting TSLP achieves positive results in asthma study

Jim Cornall -
Harbour BioMed has announced that its partner, Windward Bio, has reported positive interim results from the phase 2 portion...

Clinical trial shows knee osteoarthritis pain improvement

Jim Cornall -
Allegro NV, a Belgian biomedical company developing a nanotechnology treatment for osteoarthritis, has announced statistically significant improvements in pain...

Preclinical paper on CD73 small molecule inhibitor

Jim Cornall -
Antengene Corporation Limited has announced that a preclinical research paper evaluating the combination of ATG-037 (CD73 small molecule inhibitor)...

Positive results from relapsed/refractory B-cell lymphoma trial

Jim Cornall -
PeproMene Bio, Inc. has announced the publication in The Lancet of results from its phase 1 clinical trial evaluating...

EpilepsyGTx and Viralgen collaborating on AAV gene therapy epilepsy programme

Jim Cornall -
EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a contract development and manufacturing organisation (CDMO)...

Base to Base biotech podcast 75: AI-powered diagnostics and cancer immunotherapy

Jim Cornall -
This week, we talk to a company in Lund, Asgard Therapeutics, and its co-founder and CEO Cristiana Pires, about...

Is atherosclerosis an autoimmune disease?

Jim Cornall -
A new study in mice and patients has led to a claim that atherosclerosis meets the criteria for an...

Northway Biotech opens €61m cell therapy and personalised medicine CDMO in Lithuania

Jim Cornall -
The first dedicated cell therapy and personalised medicine centre of its kind in the Baltic states has opened in...

Eascra Biotech receives NASA contract for space-manufactured nanomedicine

Jim Cornall -
Eascra Biotech, a nanomedicine startup with a lab in Worcester, Mass., has been awarded a NASA In Space Production...

Typewriter Therapeutics emerges from stealth with $56m to pursue in vivo CAR T medicines

Jim Cornall -
Typewriter Therapeutics, Inc. has emerged from stealth with $56m in Series A financing. Typewriter is a biotech company developing safe,...

Zifo says CMC bottleneck choking drug pipeline

Jim Cornall -
The biopharma industry has invested heavily in accelerating discovery. AI, machine learning (ML), high-throughput experimentation and advanced modelling are...

How melanoma silences skin’s natural antitumour defence

Jim Cornall -
A new study by researchers from the Atopy (Allergy) Research Center of the Juntendo University Graduate School of Medicine,...

Severe asthma linked to changes in brain structure

Jim Cornall -
People living with a severe form of asthma show subtle differences in the structure of their brains compared with...

New method causes cancer cells to burn out

Jim Cornall -
Researchers at the University of Gothenburg say a new drug forces cancer cells to keep working hard even though...

Convergen raises $15m to advance therapeutics for protein aggregation diseases

Jim Cornall -
Convergen, a biotechnology company creating targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, has announced...

Cancer drug could help millions battling osteoporosis and mid-life weight gain

Jim Cornall -
An experimental cancer drug could stop osteoporosis and help women stay slim after the menopause – according to new...

Microdroplets can reduce colorectal tumour growth at lower cost

Jim Cornall -
Scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed microscopic peptide droplets that deliver large amounts of gene-silencing...

Clicklinks launched for drug discovery

Jim Cornall -
Sanyou Biopharmaceuticals Co., Ltd. has launched Clicklinks, an AI-STAL and SAI-DA powered collaborative network designed to support original drug...

Base to Base biotech podcast 74: A vision for vision, and studying pancreatic cancer

Jim Cornall -
This week, our guests are Bryan McClellan, who conducted research on pancreatic cancer as a postdoctoral fellow at Dell...

FDA first-ever treatment for warm autoimmune haemolytic anaemia

Jim Cornall -
Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY (nipocalimab-aahu) for the treatment...